Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Heart Failure Reviews
Erschienen in: Heart Failure Reviews 2/2015

01.03.2015

Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment

verfasst von: Brendan N. Putko, Kevin Wen, Richard B. Thompson, John Mullen, Miriam Shanks, Haran Yogasundaram, Consolato Sergi, Gavin Y. Oudit

Erschienen in: Heart Failure Reviews | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Anderson-Fabry disease (AFD) is a lysosomal storage disease caused by the inappropriate accumulation of globotriaosylceramide in tissues due to a deficiency in the enzyme α-galactosidase A (α-Gal A). Anderson-Fabry cardiomyopathy is characterized by structural, valvular, vascular and conduction abnormalities, and is now the most common cause of mortality in patients with AFD. Large-scale metabolic and genetic screening studies have revealed AFD to be prevalent in populations of diverse ethnic origins, and the variant form of AFD represents an unrecognized health burden. Anderson-Fabry disease is an X-linked disorder, and genetic testing is critical for the diagnosis of AFD in women. Echocardiography with strain imaging and cardiac magnetic resonance imaging using late enhancement and T1 mapping are important imaging tools. The current therapy for AFD is enzyme replacement therapy (ERT), which can reverse or prevent AFD progression, while gene therapy and the use of molecular chaperones represent promising novel therapies for AFD. Anderson-Fabry cardiomyopathy is an important and potentially reversible cause of heart failure that involves LVH, increased susceptibility to arrhythmias and valvular regurgitation. Genetic testing and cardiac MRI are important diagnostic tools, and AFD cardiomyopathy is treatable if ERT is introduced early.
Literatur
1.
Clarke JT (2007) Narrative review: Fabry disease. Ann Intern Med 146:425–433PubMed
2.
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345:9–16PubMed
3.
Rao DA, Lakdawala NK, Miller AL, Loscalzo J (2013) Clinical problem-solving. In the thick of it. N Engl J Med 368:1732–1738PubMed
4.
Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S et al (2013) The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the world heart federation. J Am Coll Cardiol 62:2046–2072PubMed
5.
Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy—a retrospective analysis from the Fabry outcome survey. Clin J Pain 23:535–542PubMed
6.
Keshav S (2006) Gastrointestinal manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS, chap 28. Oxford PharmaGenesis, Oxford
7.
Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G et al (2007) Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 157:331–337PubMed
8.
Samiy N (2008) Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 53:416–423PubMed
9.
Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS—Fabry outcome survey. J Med Genet 46:548–552PubMed
10.
Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E et al (2009) Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transpl 24:1736–1743
11.
Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ (2000) Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 48:227–235PubMed
12.
Germain DP (2001) A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. Contrib Nephrol (136): 234–240
13.
Grunfeld JP, Lidove O, Joly D, Barbey F (2001) Renal disease in Fabry patients. J Inherit Metab Dis 24(Suppl 2):71–74PubMed
14.
Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S139–S143PubMed
15.
Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudova J, Karetova D et al (2000) New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J 139:1101–1108PubMed
16.
Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J et al (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24(Suppl 2):75–83PubMed
17.
Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Arnao V, Licata G et al (2013) Neurological complications of Anderson-Fabry disease. Curr Pharm Des 19:6014–6030PubMed
18.
Elleder M, Dorazilova V, Bradova V, Belohlavek M, Kral V, Choura M et al (1990) Fabry’s disease with isolated disease of the cardiac muscle, manifesting as hypertrophic cardiomyopathy. Cas Lek Cesk 129:369–372PubMed
19.
von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG et al (1991) An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 324:395–399
20.
Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M et al (1995) An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 333:288–293PubMed
21.
Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228–1235PubMed
22.
Mignani R, Feriozzi S, Schaefer RM, Breunig F, Oliveira JP, Ruggenenti P et al (2010) Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Clin J Am Soc Nephrol 5:379–385PubMed
23.
Scriver CR (1995) The metabolic and molecular bases of inherited disease, vol II. McGraw-Hill, New York, p 2742
24.
Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S (2013) Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 58:548–552PubMed
25.
Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A et al (2012) Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 379:335–341PubMed
26.
Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH et al (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2:450–456PubMed
27.
Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40PubMedCentralPubMed
28.
Feldt-Rasmussen U, Dobrovolny R, Nazarenko I, Ballegaard M, Hasholt L, Rasmussen AK et al (2011) Diagnostic dilemma: a young woman with Fabry disease symptoms, no family history, and a “sequencing cryptic” alpha-galactosidase a large deletion. Mol Genet Metab 104:314–318PubMed
29.
Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ et al (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407–1411PubMed
30.
Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA et al (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110:1047–1053PubMed
31.
Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB et al (2011) Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry disease survey. Heart 97:1957–1960PubMed
32.
Havndrup O, Christiansen M, Stoevring B, Jensen M, Hoffman-Bang J, Andersen PS et al (2010) Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail 12:535–540PubMed
33.
van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE et al (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1–9PubMed
34.
Bach G, Rosenmann E, Karni A, Cohen T (1982) Pseudodeficiency of alpha-galactosidase A. Clin Genet 21:59–64PubMed
35.
Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ (2003) Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 22:486–492PubMed
36.
Niemann M, Rolfs A, Stork S, Bijnens B, Breunig F, Beer M et al (2014) Gene mutations versus clinically relevant phenotypes-Lyso-Gb3 defines fabry disease. Circ Cardiovasc Genet 7:8–16PubMed
37.
MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775PubMedCentralPubMed
38.
Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112–128PubMed
39.
Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J et al (2013) Fabry disease practice guidelines: recommendations of the national society of genetic counselors. J Genet Couns 22:555–564PubMed
40.
Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34–45PubMed
41.
42.
Anderson LJ, Wyatt KM, Henley W, Nikolaou V, Waldek S, Hughes DA et al (2014) Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. doi:10.​1007/​s10545-014-9717-4
43.
Desnick RJ (2007) Prenatal diagnosis of Fabry disease. Prenat Diagn 27:693–694PubMed
44.
Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077–1084PubMed
45.
Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524–529PubMed
46.
Shin SH, Kluepfel-Stahl S, Cooney AM, Kaneski CR, Quirk JM, Schiffmann R et al (2008) Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet Genomics 18:773–780PubMedCentralPubMed
47.
Linhart A (2006) The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS, chap 20. Oxford PharmaGenesis, Oxford
48.
Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M et al (2010) Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 31:1088–1097PubMedCentralPubMed
49.
Sadick N, Thomas L (2007) Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study. Heart Lung Circ 16:200–206PubMed
50.
Shanks M, Thompson RB, Paterson ID, Putko B, Khan A, Chan A et al (2013) Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Am Soc Echocardiogr 26:1407–1414PubMed
51.
Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M et al (2011) Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 4:592–601PubMed
52.
Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I et al (2013) T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 6:637–645PubMed
53.
Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M et al (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40:1668–1674PubMed
54.
Gambarin FI, Disabella E, Narula J, Diegoli M, Grasso M, Serio A et al (2010) When should cardiologists suspect Anderson-Fabry disease? Am J Cardiol 106:1492–1499PubMed
55.
Calcagnino M, O’Mahony C, Coats C, Cardona M, Garcia A, Janagarajan K et al (2011) Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease. J Am Coll Cardiol 58:88–89PubMed
56.
Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307:491–497PubMed
57.
Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA 307:483–490PubMed
58.
Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A et al (2013) Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310:959–968PubMed
59.
Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, Kantola I et al (2005) Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 28:563–573PubMed
60.
Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357–360PubMedCentralPubMed
61.
Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S et al (2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26:839–844PubMed
62.
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812–2817PubMedCentralPubMed
63.
Pochis WT, Litzow JT, King BG, Kenny D (1994) Electrophysiologic findings in Fabry’s disease with a short PR interval. Am J Cardiol 74:203–204PubMed
64.
Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96:842–846PubMed
65.
Eckart RE, Kinney KG, Belnap CM, Le TD (2000) Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry’s disease. Review of cardiovascular manifestations. Cardiology 94:208–212PubMed
66.
Acharya D, Robertson P, Kay GN, Jackson L, Warnock DG, Plumb VJ et al (2012) Arrhythmias in Fabry cardiomyopathy. Clin Cardiol 35:738–740PubMed
67.
Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463–469PubMed
68.
Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A (2003) Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107:1978–1984PubMed
69.
Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, Pintos G et al (2009) Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 132:38–44PubMed
70.
Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221–1227PubMed
71.
Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108:1299–1301PubMed
72.
Soullier C, Obert P, Doucende G, Nottin S, Cade S, Perez-Martin A et al (2012) Exercise response in hypertrophic cardiomyopathy: blunted left ventricular deformational and twisting reserve with altered systolic-diastolic coupling. Circ Cardiovasc Imaging 5:324–332PubMed
73.
Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ et al (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24:2151–2155PubMed
74.
Koeppe S, Neubauer H, Breunig F, Weidemann F, Wanner C, Sandstede J et al (2012) MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease. Int J Cardiol 160:53–58PubMed
75.
Messalli G, Imbriaco M, Avitabile G, Russo R, Iodice D, Spinelli L et al (2012) Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Radiol Med 117:19–28PubMed
76.
Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA (2011) Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 57:891–903PubMed
77.
Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G et al (2013) Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 6:392–398PubMed
78.
Desnick RJ, Wasserstein MP, Banikazemi M (2001) Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy. Contrib Nephrol (136):174–192
79.
Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L et al (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711–722PubMedCentralPubMed
80.
Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86PubMed
81.
Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE et al (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 5:2220–2228PubMedCentralPubMed
82.
Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M et al (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15:1323–1329PubMed
83.
84.
Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H (1967) Angiokeratoma corporis diffusum–Fabry’s disease. Helv Med Acta 34:67–83PubMed
85.
MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760PubMedCentralPubMed
86.
Tyson CC, Nwankwo C, Lin PH, Svetkey LP (2012) The dietary approaches to stop hypertension (DASH) eating pattern in special populations. Curr Hypertens Rep 14:388–396PubMed
87.
Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539–548PubMed
88.
89.
Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O’Callaghan MW (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119:2561–2567PubMed
90.
Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:365–370PubMedCentralPubMed
91.
Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374:1986–1996PubMed
92.
Alfadhel M, Sirrs S (2011) Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag 7:69–82PubMedCentralPubMed
93.
Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE (2014) Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis 37:341–352PubMed
94.
Pieroni M, Camporeale A, Della Bona R, Sabini A, Cosmi D, Magnolfi A et al (2013) Progression of Fabry cardiomyopathy despite enzyme replacement therapy. Circulation 128:1687–1688PubMed
95.
Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331–341PubMedCentralPubMed
96.
Hersher R (2012) Small biotechs raring to cash in on the orphan disease market. Nat Med 18:330–331PubMed
97.
Murray GJ, Anver MR, Kennedy MA, Quirk JM, Schiffmann R (2007) Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 90:307–312PubMedCentralPubMed
98.
El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2:CD006663PubMed
99.
Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S et al (2014) Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab 111:499–506PubMed
100.
Guce AI, Clark NE, Rogich JJ, Garman SC (2011) The molecular basis of pharmacological chaperoning in human alpha-galactosidase. Chem Biol 18:1521–1526PubMedCentralPubMed
101.
Suzuki Y (2013) Chaperone therapy update: fabry disease, GM1-gangliosidosis and Gaucher disease. Brain Dev 35:515–523PubMed
102.
Benjamin ER, Khanna R, Schilling A, Flanagan JJ, Pellegrino LJ, Brignol N et al (2012) Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther 20:717–726PubMedCentralPubMed
103.
Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M et al (2001) Improvement in cardiac function in the cardiac variant of Fabry’s disease with galactose-infusion therapy. N Engl J Med 345:25–32PubMed
104.
Wu X, Katz E, Della Valle MC, Mascioli K, Flanagan JJ, Castelli JP et al (2011) A pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Hum Mutat 32:965–977PubMedCentralPubMed
105.
Siekierska A, De Baets G, Reumers J, Gallardo R, Rudyak S, Broersen K et al (2012) Alpha-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. J Biol Chem 287:28386–28397PubMedCentralPubMed
106.
Lee CJ, Fan X, Guo X, Medin JA (2011) Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease. J Cardiol 57:115–122PubMed
107.
Ruiz de Garibay AP, Delgado D, Del Pozo-Rodriguez A, Solinis MA, Gascon AR (2012) Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy. Drug Des Devel Ther 6:303–310PubMedCentralPubMed
Metadaten
Titel
Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment
verfasst von
Brendan N. Putko
Kevin Wen
Richard B. Thompson
John Mullen
Miriam Shanks
Haran Yogasundaram
Consolato Sergi
Gavin Y. Oudit
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 2/2015
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-014-9452-9

Weitere Artikel der Ausgabe 2/2015

Heart Failure Reviews 2/2015 Zur Ausgabe

OriginalPaper

Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart

OriginalPaper

Nuclear imaging for cardiac amyloidosis

OriginalPaper

Cardiac amyloidosis: the great pretender

OriginalPaper

Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis

OriginalPaper

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

OriginalPaper

Echocardiography in cardiac amyloidosis

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise